RNA therapeutics are changing the way we address diseases. Applications range from gene therapy, oncology, to vaccines for infectious diseases such as COVID-19.
The performance of RNA therapeutics critically depends on its formulation. Key decisions have to be made early on in the drug development process; choosing the appropriate drug delivery method and novel excipients. Raw material source and judicious choice of chemistry, ultimately determine the quality of novel lipid excipients which, in turn, has a big impact on the performance, reproducibility, costs, and regulatory approval timelines. This webinar will propose solutions to maximize the probability of success while formulating RNA therapeutics and vaccines.
Technical Product Manager,
Shiksha Mantri is the Global Technical Product Manager for synthetic lipids and responsible for the entire GMP lipids business (portfolio and custom manufacturing). In her current role, she supports the top industry players and young start-ups in the RNA delivery and vaccines fields. She holds a PhD in Chemical Biology from the University of Oxford, U.K. and did her postdoc at ETH Zurich, Switzerland.